Bayer projects improvement in 2026 after profit decline this year

Frankfurt | Reuters — Bayer on Wednesday raised the prospect of a return to earnings growth from 2026 after a decline this year, lifting its shares to a four-month high as its CEO somewhat allayed investor impatience with his turnaround efforts.

Why it matters: Bayer is a key provider of agricultural inputs for Canadian farmers

The German maker of drugs and farming pesticides said 2025 would be the most difficult in terms of financial performance, with net sales roughly in line with the prior year and a drop in earnings and free cash flow.

Read Also

Mexico likely to seek more trade with Canada

In the face of U.S. tariffs Claudia Sheinbaum, president of Mexico, sees opportunity to grow trade between Canada and Mexico.

“The company expects improved performance from 2026 onwards,” it added.

CEO Bill Anderson has faced investor pressure to deliver on restructuring efforts and reverse what is projected to be the third consecutive annual drop in operating income in 2025.

Beyond 2026, Bayer said it was targeting an adjusted operating margin percentage in the “mid-twenties” at its Crop Science division by 2029, up from 19.4 per cent last year.

“The 2025 guidance is not particularly encouraging, but the company’s longer-term outlook and plans to address key issues offer some hope for future improvement,” Deutsche Bank analysts said in a note.

Bayer’s shares gained as much as 7.7 per cent and were up 3.9 per cent by 11:10 GMT.

The CEO is cutting managerial jobs, speeding up decision-making and slashing red tape. Anderson reaffirmed on

Wednesday he would hold off on any plans to break up Bayer’s diversified businesses for another one or two years.

The group, which is grappling with costly U.S. product liability litigation over its weedkiller Roundup, said on Wednesday it had slashed 7,000 jobs last year and cutbacks would continue.

For the fourth quarter of last year, Bayer reported a 22 per cent fall in earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for one-off items, to 2.35 billion euros (C$3.86 billion), beating a company-provided consensus of 2.27 billion euros.

It forecast adjusted EBITDA of between 9.3 billion and 9.8 billion euros (C$14.4 billion to $15.1 billion) this year, based on end-2024 foreign exchange rates. That was down from 10.1 billion in 2024 and compares with a market consensus of 9.4 billion.

— Additional reporting by Patricia Weiss